Latest Insider Transactions at Intra Cellular Therapies, Inc. (ITCI)
This section provides a real-time view of insider transactions for Intra Cellular Therapies, Inc. (ITCI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intra-Cellular Therapies, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intra-Cellular Therapies, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,443
+50.0%
|
-
|
|
Feb 18
2023
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
11,139
+50.0%
|
-
|
|
Feb 17
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
53,968
-98.44%
|
$2,698,400
$50.2 P/Share
|
|
Feb 17
2023
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,968
+50.0%
|
$647,616
$12.73 P/Share
|
|
Dec 30
2022
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
321
+0.41%
|
$16,692
$52.92 P/Share
|
|
Dec 30
2022
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
97
+1.04%
|
$5,044
$52.92 P/Share
|
|
Dec 19
2022
|
Joel S Marcus |
SELL
Open market or private sale
|
Direct |
5,000
-14.61%
|
$250,000
$50.82 P/Share
|
|
Dec 13
2022
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
33,083
-2.92%
|
$1,819,565
$55.0 P/Share
|
|
Dec 01
2022
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
50,000
-77.2%
|
$2,650,000
$53.71 P/Share
|
|
Dec 01
2022
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
$750,000
$15.47 P/Share
|
|
Nov 07
2022
|
Joel S Marcus |
SELL
Open market or private sale
|
Direct |
10,000
-12.02%
|
$520,000
$52.3 P/Share
|
|
Sep 30
2022
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
110
+1.19%
|
$5,060
$46.53 P/Share
|
|
Sep 30
2022
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
365
+0.47%
|
$16,790
$46.53 P/Share
|
|
Sep 21
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
65,164
-74.45%
|
$2,932,380
$45.64 P/Share
|
|
Sep 21
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
65,164
+50.0%
|
$977,460
$15.47 P/Share
|
|
Aug 11
2022
|
Robert L Van Nostrand |
SELL
Open market or private sale
|
Direct |
30,000
-43.61%
|
$1,680,000
$56.98 P/Share
|
|
Aug 11
2022
|
Robert L Van Nostrand |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+30.59%
|
$360,000
$12.75 P/Share
|
|
Aug 11
2022
|
Joel S Marcus |
SELL
Open market or private sale
|
Direct |
10,000
-18.44%
|
$590,000
$59.22 P/Share
|
|
Jun 30
2022
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
108
+1.18%
|
$6,156
$57.08 P/Share
|
|
Jun 30
2022
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
289
+0.37%
|
$16,473
$57.08 P/Share
|
|
May 12
2022
|
Joel S Marcus |
SELL
Open market or private sale
|
Direct |
10,000
-15.57%
|
$550,000
$55.0 P/Share
|
|
Apr 08
2022
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
86,348
-28.42%
|
$5,526,272
$64.37 P/Share
|
|
Apr 08
2022
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
86,348
+39.6%
|
$1,036,176
$12.73 P/Share
|
|
Mar 31
2022
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
257
+0.33%
|
$15,677
$61.19 P/Share
|
|
Mar 31
2022
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
126
+1.39%
|
$7,686
$61.19 P/Share
|
|
Mar 18
2022
|
Rory B Riggs |
SELL
Open market or private sale
|
Indirect |
20,637
-61.87%
|
$1,238,220
$60.99 P/Share
|
|
Mar 17
2022
|
Rory B Riggs |
SELL
Open market or private sale
|
Indirect |
141,499
-50.59%
|
$8,489,940
$60.2 P/Share
|
|
Mar 16
2022
|
Rory B Riggs |
SELL
Open market or private sale
|
Indirect |
64,534
-15.21%
|
$3,807,506
$59.13 P/Share
|
|
Mar 09
2022
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,925
+3.32%
|
$77,850
$2.84 P/Share
|
|
Mar 08
2022
|
Joel S Marcus |
SELL
Open market or private sale
|
Indirect |
15,000
-18.51%
|
$780,000
$52.57 P/Share
|
|
Mar 07
2022
|
Joel S Marcus |
SELL
Open market or private sale
|
Indirect |
5,000
-10.21%
|
$270,000
$54.52 P/Share
|
|
Mar 04
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,860
-14.32%
|
$212,300
$55.52 P/Share
|
|
Mar 02
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,177
-13.41%
|
$233,912
$56.98 P/Share
|
|
Feb 24
2022
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
22,589
-0.68%
|
$1,152,039
$51.63 P/Share
|
|
Feb 24
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
7,454
-80.92%
|
$380,154
$51.65 P/Share
|
|
Feb 24
2022
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,906
-73.51%
|
$411,112
$52.0 P/Share
|
|
Feb 24
2022
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,906
-5.2%
|
$411,112
$52.1 P/Share
|
|
Feb 24
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,046
-3.97%
|
$210,392
$52.17 P/Share
|
|
Feb 23
2022
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,589
+1.98%
|
-
|
|
Feb 23
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,454
+50.0%
|
-
|
|
Feb 23
2022
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,906
+50.0%
|
-
|
|
Feb 23
2022
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,906
+12.93%
|
-
|
|
Feb 23
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,906
+18.35%
|
-
|
|
Feb 22
2022
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
27,847
-1.25%
|
$1,531,585
$55.36 P/Share
|
|
Feb 22
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
10,443
-77.85%
|
$574,365
$55.36 P/Share
|
|
Feb 22
2022
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
11,139
-79.58%
|
$612,645
$55.33 P/Share
|
|
Feb 22
2022
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,139
-10.39%
|
$612,645
$55.22 P/Share
|
|
Feb 22
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,177
-6.85%
|
$229,735
$55.16 P/Share
|
|
Feb 18
2022
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,847
+2.42%
|
-
|
|
Feb 18
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,443
+50.0%
|
-
|